NASDAQ:LOXO - Loxo Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$176.93 -1.99 (-1.11 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$176.93
Today's Range$175.25 - $180.55
52-Week Range$69.00 - $208.95
Volume994,878 shs
Average Volume632,158 shs
Market Capitalization$5.32 billion
P/E Ratio-33.32
Dividend YieldN/A
Beta2.45

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LOXO
CUSIPN/A
Phone203-653-3880

Debt

Debt-to-Equity RatioN/A
Current Ratio3.52
Quick Ratio3.52

Price-To-Earnings

Trailing P/E Ratio-33.32
Forward P/E Ratio221.16
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.30 million
Price / Sales249.86
Cash FlowN/A
Price / CashN/A
Book Value$12.63 per share
Price / Book14.01

Profitability

EPS (Most Recent Fiscal Year)($5.31)
Net Income$-148,870,000.00
Net MarginsN/A
Return on Equity-21.73%
Return on Assets-14.55%

Miscellaneous

Employees59
Outstanding Shares30,080,000

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. During the same period in the previous year, the business posted ($0.96) EPS. View Loxo Oncology's Earnings History.

What price target have analysts set for LOXO?

12 brokers have issued 12 month price targets for Loxo Oncology's shares. Their predictions range from $122.00 to $235.00. On average, they expect Loxo Oncology's stock price to reach $180.3333 in the next twelve months. View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (5/8/2018)
  • 2. Cann analysts commented, "Loxo’s Q4:17 loss per share was $0.69 compared to our estimated loss of $1.18. The lower than estimated loss resulted from collaboration revenue recognition of $21.3 million. This was partially offset by operating expenses being 17.9% higher than estimated. Higher operating expenses arose primarily from higher R&D. As a result, we are increasing our estimated R&D expenses for 2018 and 2019. There were no other remarkable variances in the quarter. The completion of the rolling NDA submission for larotrectinib is expected in March 2018, and the Marketing Authorization Application submission in the EU is expected in 2018. This submission is being led by Bayer." (3/1/2018)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 46)
  • Ms. Jennifer Burstein, Sr. VP of Fin. (Age 46)
  • Mr. Jacob S. Van Naarden, Chief Bus. Officer (Age 33)
  • Ms. Sara Slifka, VP of Bus. Operations & Program Management
  • Ms. Jennifer L. Kronick, VP of HR

Has Loxo Oncology been receiving favorable news coverage?

News articles about LOXO stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Loxo Oncology earned a coverage optimism score of 0.13 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.04%), OppenheimerFunds Inc. (3.49%), ACCESS INDUSTRIES MANAGEMENT, LLC (2.85%), Lord Abbett & CO. LLC (2.22%), Victory Capital Management Inc. (1.48%) and Rock Springs Capital Management LP (1.05%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

Which major investors are selling Loxo Oncology stock?

LOXO stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., DAFNA Capital Management LLC, Eventide Asset Management LLC, Prudential Financial Inc., BlackRock Inc., Candriam Luxembourg S.C.A., OppenheimerFunds Inc. and JPMorgan Chase & Co.. Company insiders that have sold Loxo Oncology company stock in the last year include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Insider Buying and Selling for Loxo Oncology.

Which major investors are buying Loxo Oncology stock?

LOXO stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Frontier Capital Management Co. LLC, KBC Group NV, Federated Investors Inc. PA, American Century Companies Inc., UBS Group AG, Sei Investments Co. and Mackay Shields LLC. View Insider Buying and Selling for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $176.93.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $5.32 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (LOXO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Loxo Oncology (NASDAQ:LOXO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Loxo Oncology in the last 12 months. Their average twelve-month price target is $180.3333, suggesting that the stock has a possible upside of 1.92%. The high price target for LOXO is $235.00 and the low price target for LOXO is $122.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.923.093.093.11
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $180.3333$157.75$121.50$92.00
Price Target Upside: 1.92% upside5.84% downside1.25% upside24.39% upside

Loxo Oncology (NASDAQ:LOXO) Consensus Price Target History

Price Target History for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2018Ifs SecuritiesDowngradeStrong-Buy ➝ Market PerformLowView Rating Details
6/4/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Buy$182.00 ➝ $221.00HighView Rating Details
6/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.00HighView Rating Details
6/4/2018CitigroupBoost Price TargetBuy$235.00HighView Rating Details
6/4/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$190.00 ➝ $225.00HighView Rating Details
6/4/2018William BlairReiterated RatingBuyHighView Rating Details
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight$200.00MediumView Rating Details
5/17/2018BTIG ResearchReiterated RatingBuy$156.00HighView Rating Details
3/1/2018CannReiterated RatingBuy$122.00HighView Rating Details
2/22/2018CIBCInitiated CoverageOutperform ➝ Outperform$132.00LowView Rating Details
2/22/2018OppenheimerInitiated CoverageOutperform$132.00LowView Rating Details
9/28/2017CowenReiterated RatingBuyLowView Rating Details
2/8/2017Jefferies Financial GroupInitiated CoverageBuy$50.00N/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

Loxo Oncology (NASDAQ:LOXO) Earnings History and Estimates Chart

Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ:LOXO) Earnings Estimates

2018 EPS Consensus Estimate: $0.50
2019 EPS Consensus Estimate: $1.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.19)($0.79)($0.99)
Q2 20182($1.22)($0.88)($1.05)
Q3 20182($1.26)$4.02$1.38
Q4 20182($0.81)$3.13$1.16
Q1 20191($0.90)($0.90)($0.90)
Q2 20191($0.90)($0.90)($0.90)
Q3 20191$1.67$1.67$1.67
Q4 20191$1.61$1.61$1.61

Loxo Oncology (NASDAQ LOXO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.13)($0.12)$12.72 millionViewListenView Earnings Details
3/1/2018Q4 2017($1.22)($0.69)$21.30 millionViewListenView Earnings Details
11/2/2017Q3 2017($1.38)($1.12)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.99)($1.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Loxo Oncology (NASDAQ:LOXO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Loxo Oncology (NASDAQ LOXO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.10%
Insider Trading History for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology (NASDAQ LOXO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2018Timothy M MaylebenDirectorSell10,000$179.55$1,795,500.0059,732View SEC Filing  
5/15/2018Joshua H BilenkerCEOSell15,000$136.51$2,047,650.00View SEC Filing  
5/15/2018Naarden Jacob VanInsiderSell3,082$137.42$423,528.44View SEC Filing  
4/25/2018Joshua H BilenkerCEOSell15,000$131.12$1,966,800.00190,207View SEC Filing  
4/25/2018Naarden Jacob VanInsiderSell3,082$131.23$404,450.861,541View SEC Filing  
4/24/2018Jennifer BursteinVPSell1,700$131.65$223,805.001,700View SEC Filing  
4/20/2018Lori Anne KunkelDirectorSell5,000$132.68$663,400.0010,940View SEC Filing  
3/14/2018Joshua H BilenkerCEOSell15,000$131.54$1,973,100.00190,207View SEC Filing  
3/14/2018Naarden Jacob VanInsiderSell3,082$131.41$405,005.621,541View SEC Filing  
3/13/2018Jennifer BursteinVPSell1,700$131.33$223,261.001,700View SEC Filing  
2/13/2018Joshua H BilenkerCEOSell15,000$96.57$1,448,550.00190,207View SEC Filing  
2/13/2018Naarden Jacob VanInsiderSell3,082$96.34$296,919.881,541View SEC Filing  
2/12/2018Jennifer BursteinVPSell1,700$93.24$158,508.001,700View SEC Filing  
1/22/2018Avi Z NaiderDirectorSell15,000$100.00$1,500,000.00141,118View SEC Filing  
1/17/2018Joshua H BilenkerCEOSell15,000$88.21$1,323,150.00190,207View SEC Filing  
1/17/2018Naarden Jacob VanInsiderSell3,082$88.21$271,863.221,541View SEC Filing  
1/16/2018Jennifer BursteinVPSell1,500$87.50$131,250.001,500View SEC Filing  
12/20/2017Timothy M. MaylebenDirectorSell10,000$80.49$804,900.00View SEC Filing  
12/19/2017Aisling Capital Iii LpMajor ShareholderSell250,000$80.50$20,125,000.00View SEC Filing  
12/15/2017Joshua H BilenkerCEOSell15,000$81.12$1,216,800.00190,207View SEC Filing  
12/15/2017Naarden Jacob VanInsiderSell3,082$81.19$250,227.581,541View SEC Filing  
12/14/2017Jennifer BursteinVPSell1,700$83.27$141,559.001,700View SEC Filing  
12/8/2017David P BonitaDirectorSell250,000$82.50$20,625,000.00View SEC Filing  
11/28/2017Joshua H BilenkerCEOSell15,000$74.45$1,116,750.00182,707View SEC Filing  
11/28/2017Naarden Jacob VanInsiderSell3,082$74.50$229,609.001,541View SEC Filing  
11/27/2017Jennifer BursteinVPSell1,700$74.82$127,194.001,700View SEC Filing  
11/22/2017Aisling Capital Iii LpMajor ShareholderSell500,000$75.00$37,500,000.00View SEC Filing  
11/22/2017Orbimed Advisors LlcDirectorSell267,000$75.00$20,025,000.0013,000View SEC Filing  
11/20/2017Keith T FlahertyDirectorSell7,250$75.99$550,927.5012,493View SEC Filing  
11/16/2017Orbimed Advisors LlcDirectorSell270,000$74.26$20,050,200.00View SEC Filing  
11/2/2017Lori Anne KunkelDirectorSell5,000$84.91$424,550.0015,040View SEC Filing  
10/31/2017Joshua H BilenkerCEOSell7,500$86.49$648,675.00196,207View SEC Filing  
10/31/2017Naarden Jacob VanInsiderSell1,541$86.52$133,327.321,541View SEC Filing  
10/30/2017Jennifer BursteinVPSell1,700$87.19$148,223.001,700View SEC Filing  
10/16/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00144,118View SEC Filing  
9/19/2017Joshua H BilenkerCEOSell15,000$89.02$1,335,300.00196,207View SEC Filing  
9/19/2017Naarden Jacob VanInsiderSell3,082$89.00$274,298.001,541View SEC Filing  
9/18/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00149,118View SEC Filing  
9/18/2017Jennifer BursteinVPSell1,700$89.10$151,470.001,700View SEC Filing  
9/18/2017Joshua H BilenkerCEOSell7,500$89.25$669,375.00196,207View SEC Filing  
9/18/2017Naarden Jacob VanInsiderSell1,541$89.20$137,457.201,541View SEC Filing  
9/13/2017Avi Z NaiderDirectorSell5,000$90.00$450,000.00154,118View SEC Filing  
8/22/2017Lori Anne KunkelDirectorSell10,000$75.17$751,700.0016,840View SEC Filing  
8/21/2017Keith T FlahertyDirectorSell7,250$72.26$523,885.0020,432View SEC Filing  
8/15/2017Joshua H BilenkerCEOSell15,000$73.56$1,103,400.00196,207View SEC Filing  
8/15/2017Naarden Jacob VanInsiderSell3,082$73.57$226,742.741,541View SEC Filing  
8/14/2017Jennifer BursteinVPSell1,700$73.73$125,341.001,700View SEC Filing  
8/14/2017Joshua H BilenkerCEOSell7,500$73.73$552,975.00196,207View SEC Filing  
8/14/2017Naarden Jacob VanInsiderSell1,541$73.73$113,617.931,541View SEC Filing  
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.5027,141View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.5038,732View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.0045,982View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.0060,482View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50159,118View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Loxo Oncology (NASDAQ LOXO) News Headlines

Source:
DateHeadline
Notable ETF Outflow Detected - XBI, MDGL, IMMU, LOXONotable ETF Outflow Detected - XBI, MDGL, IMMU, LOXO
www.nasdaq.com - June 13 at 5:02 PM
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The FedASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
seekingalpha.com - June 13 at 5:02 PM
Timothy M. Mayleben Sells 10,000 Shares of Loxo Oncology Inc (LOXO) StockTimothy M. Mayleben Sells 10,000 Shares of Loxo Oncology Inc (LOXO) Stock
www.americanbankingnews.com - June 11 at 7:32 PM
Todays Research Reports on Trending Tickers: Loxo Oncology and Geron CorporationToday's Research Reports on Trending Tickers: Loxo Oncology and Geron Corporation
finance.yahoo.com - June 11 at 8:41 AM
Heres Why Loxo Oncology Stock Gained 40.8% in MayHere's Why Loxo Oncology Stock Gained 40.8% in May
www.fool.com - June 8 at 5:03 PM
Here's Why Loxo Oncology Stock Gained 40.8% in MayHere's Why Loxo Oncology Stock Gained 40.8% in May
finance.yahoo.com - June 8 at 5:03 PM
Loxo Oncology Inc (LOXO) Given Consensus Recommendation of "Buy" by BrokeragesLoxo Oncology Inc (LOXO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 8 at 3:56 PM
3 Cancer Stocks That Could Soar in the Second Half of 20183 Cancer Stocks That Could Soar in the Second Half of 2018
finance.yahoo.com - June 8 at 8:42 AM
Loxo Oncology Inc (LOXO) Expected to Announce Quarterly Sales of $39.60 MillionLoxo Oncology Inc (LOXO) Expected to Announce Quarterly Sales of $39.60 Million
www.americanbankingnews.com - June 8 at 4:27 AM
Zacks: Analysts Anticipate Loxo Oncology Inc (LOXO) to Announce $0.12 EPSZacks: Analysts Anticipate Loxo Oncology Inc (LOXO) to Announce $0.12 EPS
www.americanbankingnews.com - June 6 at 5:17 AM
Loxo Oncology (LOXO) Lowered to Market Perform at Ifs SecuritiesLoxo Oncology (LOXO) Lowered to Market Perform at Ifs Securities
www.americanbankingnews.com - June 5 at 10:08 AM
Interesting LOXO Put And Call Options For July 20thInteresting LOXO Put And Call Options For July 20th
www.nasdaq.com - June 5 at 8:39 AM
Loxo shares surge 8% on early-stage cancer drug trialLoxo shares surge 8% on early-stage cancer drug trial
www.marketwatch.com - June 4 at 4:50 PM
Options Traders Expect Huge Moves in Loxo Oncology (LOXO) StockOptions Traders Expect Huge Moves in Loxo Oncology (LOXO) Stock
finance.yahoo.com - June 4 at 4:50 PM
Loxo Oncology Knocks It Out of the Park for Second Year in a RowLoxo Oncology Knocks It Out of the Park for Second Year in a Row
www.bloomberg.com - June 4 at 4:50 PM
Merck emerges as key winner at ASCO conferenceMerck emerges as key winner at ASCO conference
finance.yahoo.com - June 4 at 4:50 PM
Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% TodayWhy #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today
finance.yahoo.com - June 4 at 4:50 PM
Here Are Winners And Losers From 2018's Biggest Cancer Drug MeetingHere Are Winners And Losers From 2018's Biggest Cancer Drug Meeting
finance.yahoo.com - June 4 at 4:50 PM
Citigroup Raises Loxo Oncology (LOXO) Price Target to $235.00Citigroup Raises Loxo Oncology (LOXO) Price Target to $235.00
www.americanbankingnews.com - June 4 at 2:51 PM
Loxo Oncology (LOXO) Receives "Overweight" Rating from Morgan StanleyLoxo Oncology (LOXO) Receives "Overweight" Rating from Morgan Stanley
www.americanbankingnews.com - June 4 at 2:51 PM
Stifel Nicolaus Increases Loxo Oncology (LOXO) Price Target to $225.00Stifel Nicolaus Increases Loxo Oncology (LOXO) Price Target to $225.00
www.americanbankingnews.com - June 4 at 2:07 PM
JMP Securities Reiterates $221.00 Price Target for Loxo Oncology (LOXO)JMP Securities Reiterates $221.00 Price Target for Loxo Oncology (LOXO)
www.americanbankingnews.com - June 4 at 12:03 PM
Loxo Oncology (LOXO) Given "Buy" Rating at William BlairLoxo Oncology (LOXO) Given "Buy" Rating at William Blair
www.americanbankingnews.com - June 4 at 10:08 AM
Loxo Oncology up 15% premarket on LOXO-292 dataLoxo Oncology up 15% premarket on LOXO-292 data
seekingalpha.com - June 4 at 8:47 AM
Five key takeaways from ASCO, the worlds largest cancer research conferenceFive key takeaways from ASCO, the world's largest cancer research conference
finance.yahoo.com - June 4 at 8:47 AM
Conquering cancer in the Windy CityConquering cancer in the Windy City
finance.yahoo.com - June 2 at 8:57 AM
Loxo Oncology posts improved results for newest cancer drugLoxo Oncology posts improved results for newest cancer drug
finance.yahoo.com - June 2 at 8:57 AM
Loxo Oncologys Candidates Are Impressive, Piper Jaffray Says In Bullish InitiationLoxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation
finance.yahoo.com - May 31 at 5:08 PM
3 Things In Biotech, May 30: Big News For This Giant3 Things In Biotech, May 30: Big News For This Giant
seekingalpha.com - May 31 at 9:01 AM
Loxo Oncology (LOXO) Coverage Initiated by Analysts at Piper Jaffray CompaniesLoxo Oncology (LOXO) Coverage Initiated by Analysts at Piper Jaffray Companies
www.americanbankingnews.com - May 30 at 5:28 PM
FDA accepts Loxos marketing application for larotrectinib for NTRK fusion cancers, action date November 26FDA accepts Loxo's marketing application for larotrectinib for NTRK fusion cancers, action date November 26
seekingalpha.com - May 29 at 5:01 PM
Financial Exchange Stock Talk: Joe McCann On Loxo OncologyFinancial Exchange Stock Talk: Joe McCann On Loxo Oncology
seekingalpha.com - May 29 at 5:01 PM
Loxo Oncology (LOXO) Announces FDA Accepts Larotrectinib NDA and Grants Priority ReviewLoxo Oncology (LOXO) Announces FDA Accepts Larotrectinib NDA and Grants Priority Review
www.streetinsider.com - May 29 at 8:44 AM
FDA Accepts Larotrectinib New Drug Application and Grants Priority ReviewFDA Accepts Larotrectinib New Drug Application and Grants Priority Review
finance.yahoo.com - May 29 at 8:44 AM
Loxo-Bayer cancer drug gets priority review from FDALoxo-Bayer cancer drug gets priority review from FDA
finance.yahoo.com - May 29 at 8:44 AM
$23.30 Million in Sales Expected for Loxo Oncology (LOXO) This Quarter$23.30 Million in Sales Expected for Loxo Oncology (LOXO) This Quarter
www.americanbankingnews.com - May 22 at 5:29 AM
Zacks: Brokerages Expect Loxo Oncology (LOXO) Will Post Earnings of $0.08 Per ShareZacks: Brokerages Expect Loxo Oncology (LOXO) Will Post Earnings of $0.08 Per Share
www.americanbankingnews.com - May 20 at 1:19 AM
Does a Blue Ribbon Make This Biotech Stock a Buy Now?Does a Blue Ribbon Make This Biotech Stock a Buy Now?
finance.yahoo.com - May 19 at 5:22 PM
This Tiny Cancer Drug Upstart Just Got Even More InterestingThis Tiny Cancer Drug Upstart Just Got Even More Interesting
finance.yahoo.com - May 18 at 5:20 PM
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
finance.yahoo.com - May 18 at 5:20 PM
Loxo Oncology (LOXO) Price Target Raised to $178.00 at CitigroupLoxo Oncology (LOXO) Price Target Raised to $178.00 at Citigroup
www.americanbankingnews.com - May 18 at 3:09 PM
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Jounce TherapeuticsToday’s Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics
finance.yahoo.com - May 18 at 9:23 AM
Loxo Oncology Sees Unusually Large Options Volume (LOXO)Loxo Oncology Sees Unusually Large Options Volume (LOXO)
www.americanbankingnews.com - May 18 at 7:41 AM
Stock Traders Buy High Volume of Put Options on Loxo Oncology (LOXO)Stock Traders Buy High Volume of Put Options on Loxo Oncology (LOXO)
www.americanbankingnews.com - May 18 at 6:46 AM
Loxo Oncology Inc. (LOXO) Has Jumped To A New High On Study ResultsLoxo Oncology Inc. (LOXO) Has Jumped To A New High On Study Results
www.nasdaq.com - May 17 at 5:36 PM
Heres Why Loxo Oncology Rose as Much as 23.3% TodayHere's Why Loxo Oncology Rose as Much as 23.3% Today
www.msn.com - May 17 at 5:36 PM
Loxo Oncology shares surge 21% on preview of cancer drug trial dataLoxo Oncology shares surge 21% on preview of cancer drug trial data
finance.yahoo.com - May 17 at 5:36 PM
Here's Why Loxo Oncology Rose as Much as 23.3% TodayHere's Why Loxo Oncology Rose as Much as 23.3% Today
finance.yahoo.com - May 17 at 5:36 PM
Loxo Oncology (LOXO) PT Raised to $190.00Loxo Oncology (LOXO) PT Raised to $190.00
www.americanbankingnews.com - May 17 at 4:43 PM
Loxo Oncology (LOXO) PT Set at $182.00 by JMP SecuritiesLoxo Oncology (LOXO) PT Set at $182.00 by JMP Securities
www.americanbankingnews.com - May 17 at 4:33 PM

SEC Filings

Loxo Oncology (NASDAQ:LOXO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Loxo Oncology (NASDAQ:LOXO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Loxo Oncology (NASDAQ LOXO) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.